BMO Capital lowered its price target for Stryker to $317 and also cut its earnings estimates. Stryker revised its 2026 organic growth and EPS outlook, while the market's reaction to the company's earnings trajectory has been mixed.
BMO Capital lowered its price target for medical technology company Stryker Corporation from $369 to $317. It maintained its Outperform rating. Stryker shares are currently trading at $276.43, down 11.5% over the past week and near their 52-week low.
The company revised its earnings estimates this week following comments at a conference hosted by a competitor. It projects third-quarter organic growth of 10.2%, cut its revenue estimate by $46 million and reduced its EPS estimate by $0.01. It also lowered its full-year 2026 revenue estimate by $71 million.
BMO expects organic growth of 8.4% in 2026, including 11.1% in the fourth quarter. Stryker's guidance range is 8.3% to 9.3%. Its 2026 EPS estimate was reduced by $0.02 to $14.97, slightly below the company's guidance range.
In its latest earnings, Stryker reported adjusted EPS of $3.69 and revenue of $6.6 billion for the second quarter of fiscal 2026, exceeding Wall Street estimates of $3.49 in EPS and $6.58 billion in revenue. Wolfe Research raised its price target from $350 to $375 while maintaining an Outperform rating. Wells Fargo, Citizens and others also lowered their price targets, while maintaining their ratings.